Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE Study

NCT04823247 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT04823247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04823247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE Study
Lead sponsor
Almirall, S.A.
Phase
Observational
Overall status
Completed
Start date
November 22, 2021
Completion date
January 9, 2025
Enrollment
782 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis